The global blood lancets market size was valued at USD 1,267.60 million in 2022. It is estimated to reach USD 2,730.43 billion by 2031, growing at a CAGR of 8.9% during the forecast period (2023–2031). Factors like the rising prevalence of chronic diseases and increasing reimbursement regulations drive the market growth.
A blood lancet, often known as a lancet, is a small medical tool used to collect capillary blood samples. Lancets are used to make microscopic punctures in the skin, similar to those used for fingerstick blood samples. Despite having a pointed end and a double-edged blade, it resembles a lancet manufactured in the scalpel style. It might even be a pointed needle. People with diabetes often use these devices to maintain constant blood sugar levels. These gadgets are simple to operate and are now often utilized in home healthcare.
Chronic diseases like diabetes, high cholesterol, and others have become more common in recent years. For instance, according to the Centers for Disease Control (CDC), there were 30.3 million cases of diabetes in 2017, representing 9.4% of the nation's population. In addition, 23.5 million people, or 7.2% of the population, have diabetes. People are increasingly using blood lancets to check their blood sugar levels, which is expected to drive market growth over the forecast period.
Blood sugar lancet reimbursement policies are available, especially in industrialized nations like the U.S., the U.K., and Germany. Blood lancets are expensive medical equipment since they must be replaced every six to eight months. As a result, most people prefer healthcare plans that help pay for expensive medical equipment. Blood lancets used in glucose test strips, glucose meters, and diabetes testing equipment all have reimbursement schemes available. For instance, Medicare in the U.S. pays about 80% of the price of blood lancets. The American Association of Diabetes Educators also released a compensation scenario for primary caregivers, specifying that Medicare will cover the service costs of diabetes patients. Such factors drive market growth.
Most diabetic patients are ignorant about their condition. The American Diabetes Association reported that in 2018 of the 30.3 million persons with diabetes, 23.1 million had their condition officially diagnosed, while 7.2 million remained undiagnosed. Similarly, people with other chronic diseases like high cholesterol are unaware they have it. Therefore, the market's expansion is hampered by patients' lack of knowledge regarding using blood lancets. Patients not using the lancet device may experience fear or anxiety before the operation, which could elevate stress levels and cause them to forego required tests. Limited patient awareness may factor in the apprehension and fear of blood samples, hindering market growth.
User-friendly blood lancet design can enhance the patient experience and compliance. Lancet usage anxiety can be lessened and eased by ergonomic designs that offer a secure grasp, simple handling, and intuitive operation. The loading and disposal of lancets can be made simpler, which can improve the user experience. It is also possible to integrate blood lancets with digital health solutions, enhancing prospects for data management and patient monitoring.
In addition, a seamless connection between lancets and blood glucose meters or mobile apps is possible, enabling automatic data gathering, processing, and tracking. Patients and medical professionals will be better able to manage and treat their blood glucose levels with the use of this connection. Such factors are expected to create opportunities for market growth over the forecast period.
| Study Period | 2019-2031 | CAGR | 8.9% |
| Historical Period | 2019-2021 | Forecast Period | 2023-2031 |
| Base Year | 2022 | Base Year Market Size | USD 1,267.60 Million |
| Forecast Year | 2031 | Forecast Year Market Size | USD 2730.43 Billion |
| Largest Market | Asia Pacific | Fastest Growing Market | Europe |
Based on region, the global blood lancets market is bifurcated into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.
Asia-Pacific is the most significant global market shareholder and is estimated to grow at a CAGR of 10.12% over the forecast period. Due to the region's growing awareness of diabetes, high cholesterol, and other chronic illnesses, the Asia-Pacific market is predicted to expand quickly over the forecast period. China had a sizable share in 2018 and is predicted to keep leading over the projection period. The increased need for efficient diabetes care and a significant number of healthcare changes are contributing factors to the growth of the blood lancets market. The Asia-Pacific market is expanding primarily due to increased demand for sophisticated healthcare services in rising economies like China and India. Furthermore, the Asia-Pacific area had 120.6 million undiagnosed diabetics in 2015, according to the IDF Atlas 7th edition, suggesting that this market offers significant prospects for lancet producers.
Additionally, compared to the previous ten years, diabetes prevalence has dramatically grown in this area. The fast modernization that results from an obesogenic atmosphere is one of the primary causes of the increase in diabetes patients. About 80–90% of people with diabetes in highly populated nations go undiagnosed, compared to 30% in high-income nations. These elements are anticipated to accelerate the market expansion for blood lancets in the Asia-Pacific region.
Europe is estimated to exhibit a CAGR of 9.4% over the forecast period. The rising elderly population in this region is a factor driving the market expansion for blood lancets. For instance, 18.5% of Europe's population, as of 2015, was 65 years of age or older, according to Eurostat. Therefore, the market for blood lancets is anticipated to develop as the elderly population rises and lifestyle illnesses become more common. In recent years, the frequency of elevated cholesterol has been rising at an alarming pace throughout Europe. For instance, the WHO reports that the prevalence of high cholesterol issues is highest in Europe. Additionally, a rise in the number of diabetic patients in Europe presents sizeable market prospects for the continent's makers of diabetes care devices.
North America is expected to witness a surging need over the forecast period due to the rise in chronic illness prevalence and the implementation of homecare diabetic management. In this region, blood lancets have significantly increased in recent years. Blood lancets have been one of the most often used types of home care in the U.S. in the past few years as a result of their tremendous rise. Its increased use is mostly due to its effectiveness in glucose monitoring and technological advancements like developing non-invasive lancing devices. Diabetes has also grown to be a major issue in this region. The prevalence of diabetes is rising significantly in the U.S. For instance, the Centers for Disease Control and Prevention estimate that over 100 million persons in the United States currently have diabetes or prediabetes. In 2015, diabetes was the sixth most common cause of mortality in the United States. Thus, it is projected that rising diabetes prevalence in this area would fuel the expansion of the blood lancet market.
In LAMEA, Lancets are increasingly in demand to manage diabetes. Blood lancets help achieve the objective of guaranteeing that everyone has access to healthcare. The market for blood lancets is expected to develop soon due to its low cost and simplicity of monitoring. However, it is projected that favorable government policies, such as increased financing and awareness for diabetes treatment, will accelerate the growth of the blood lancets market. In South and Central America, 8.0 and 11.3% of adults have diabetes, with Brazil having the greatest prevalence. This information was obtained from the International Diabetes Federation. In 2018, there were about 250,000 adult deaths from diabetes, with Brazil accounting for half of those fatalities.
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
The global blood lancets market is bifurcated into type and end-user
Based on type, the global market is bifurcated into standard, safety blood lancets, and vacuum blood lancets.
The standard lancets segment dominates the global market and is estimated to exhibit a CAGR of 8.4% over the forecast period. In order to access the capillary blood, a typical blade lancet must penetrate deeply into the skin. For each poke, patients must use a fresh lancet. Standard blood lancets become more uncomfortable repeatedly because the blade gets dull. The reuse of blood lancets increases the danger of disease transmission. For most diabetic patients worldwide, using a blood lancet to collect a blood sample for self-monitoring blood sugar levels has become standard practice. Significant technical advancements have also led to improvements in pain and wound healing, lower costs, and more integration with other blood glucose monitoring components, such as the connection of the lancing device with the glucose monitor.
Based on end-users, the global market is bifurcated into hospitals and clinics, blood banks, homecare, and others.
The homecare segment owns the highest market share and is predicted to exhibit a CAGR of 9.1% over the forecast period. The usage of blood lancets for home healthcare purposes is rising significantly. The usage of blood lancets for home healthcare has expanded since glucose monitoring kits for diabetic patients became available. They are the ideal instrument for diabetes self-diagnosis and monitoring due to their simple design and ease of usage. The market growth for the homecare category is projected to be driven by patients being more aware of the need to monitor their blood glucose levels.
